on 23 Feb 2023
Last Applicant/ Owned by
Emil-von-Behring Str. 76
Marburg
DE
D-35041
Serial Number
97148205 filed on 30th Nov 2021
Registration Number
N/A
Correspondent Address
Scott D. Woldow
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bRead More
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
No 97148205
No Service/Collective Mark
No 034845.313
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
23rd Feb 2023 | ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION |
23rd Feb 2023 | ABANDONMENT - AFTER PUBLICATION |
22nd Feb 2023 | TEAS EXPRESS ABANDONMENT RECEIVED |
31st Jan 2023 | EXTENSION OF TIME TO OPPOSE RECEIVED |
03rd Jan 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
03rd Jan 2023 | PUBLISHED FOR OPPOSITION |
14th Dec 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
01st Dec 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
05th Nov 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
05th Nov 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |